CommentaryWhich trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis
Section snippets
Transparency declaration
TMW is a Wellcome Clinical Career Development Fellow (214560/Z/18/Z) and JAW is a Wellcome Sir Henry Dale Fellow (223253/Z/21/Z). The other authors declare that they have no conflict of interest to declare.
Financial report
No external funding was received for writing this article, although the authors would like to acknowledge the long-term support provided by the Wellcome Trust, UK, to the Vietnam Africa Asia Programme and the Programme's previous and ongoing TBM clinical trials.
References (15)
- et al.
Tuberculous meningitis: progress and remaining questions
Lancet Neurol
(2022) - et al.
Tuberculosis: progress and advances in the development of new drugs, treatment regimens, and host-directed therapies
Lancet Infect Dis
(2018) - et al.
Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: a case series
Med
(2022) - et al.
Tuberculous meningitis international research consortium. Tuberculous meningitis
Nat Rev Neurol
(2017) - et al.
Intensified antituberculosis therapy in adults with tuberculous meningitis
N Engl J Med
(2016) - et al.
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis
Antimicrob Agents Chemother
(2011) - et al.
Tuberculous meningitis international research consortium. Host directed therapies for tuberculous meningitis
Wellcome Open Res
(2020)
There are more references available in the full text version of this article.
Cited by (0)
© 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.